USPH

U.S. Physical Therapy, Inc. (USPH) - Q1 2026 Filing Summary

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended March 31, 2026. U.S. Physical Therapy, Inc. operates through two reportable segments: Physical Therapy Operations (outpatient clinics and home care) and Industrial Injury Prevention (IIP) services. As of March 31, 2026, the Company operated or managed a total of 783 clinics, an increase from 766 in the prior year period, driven by the addition of 15 clinics and the closure of 12.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Net revenue increased 7.9% year-over-year to $198.3 million, driven by a 6.9% increase in patient visits and a slight increase in net rate per visit.
• Profitability Decline: Operating income decreased 36.5% to $12.5 million. This was primarily due to a $2.0 million loss on the change in fair value of contingent earn-out consideration (compared to a $4.8 million gain in Q1 2025) and increased corporate office costs.
• EPS Volatility: GAAP EPS turned negative at $(0.12) due to a $9.4 million charge to retained earnings for the revaluation of redeemable non-controlling interests, which is excluded from net income but included in the EPS calculation. Non-GAAP Operating Results per share remained stable at $0.46.
• Debt Expansion: Total debt principal increased to $205.4 million from $163.1 million, largely due to increased utilization of the revolving credit facility to fund acquisitions and working capital.
• Acquisitions: The Company completed two significant acquisitions in Q1 2026: a 70% interest in an IIP business ($15.0 million) and a 50% interest in an eight-clinic practice ($6.2 million).

Guidance, Outlook, and Risks

• Capital Structure Update: On April 14, 2026 (subsequent to the period end), the Company entered into a new $450 million credit facility (replacing the prior $325 million facility) with a maturity date of April 14, 2031. This includes a $275 million revolver and a $175 million term loan.
• Management Changes: The Chief Financial Officer, Mr. Carey Hendrickson, resigned effective April 24, 2026. Mr. Jason Curtis assumed the role of Interim CFO.
• Dividends: The Board declared a quarterly dividend of $0.46 per share, payable June 12, 2026.
• Key Risks:
  • Reimbursement Rates: Ongoing uncertainty regarding Medicare and third-party payor reimbursement rates and regulatory changes.
  • Contingent Consideration: Significant volatility in earnings due to fair value adjustments of earn-out liabilities tied to acquisition performance.
  • Redeemable Non-Controlling Interests: The Company holds significant temporary equity ($313.4 million) subject to put/call rights, which can impact EPS calculations and liquidity requirements upon redemption.
  • Regulatory Compliance: Risks associated with False Claims Act litigation and audits by CMS and other agencies.

Investor Verification Checklist

• Verify Non-GAAP Reconciliations: Confirm the specific adjustments made to reach Adjusted EBITDA ($20.2M) and Operating Results ($7.0M) to understand the core operational performance versus GAAP results.
• Assess Contingent Liability Exposure: Review the fair value of contingent earn-out obligations ($5.8 million) and the specific performance metrics triggering future payments.
• Monitor Debt Covenants: Verify compliance with the new $450 million credit facility covenants, specifically the Consolidated Leverage Ratio (max 2.5:1.0) and Fixed Charge Coverage Ratio.
• Track Clinic Count and Same-Store Metrics: Analyze the impact of the 15 new clinics and 12 closures on same-store revenue growth and average daily visits per clinic (31.8 in Q1 2026).
• Review Non-Controlling Interest Dynamics: Understand the $313.4 million redeemable non-controlling interest balance and the potential cash outflow required if put rights are exercised by partners.